- 1 Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-
- 2 report Jewish ancestry

6

- 4 Ruth I. Tennen¹, Sarah B. Laskey¹, Bertram L. Koelsch¹, Matthew H. McIntyre¹, The 23andMe
- 5 Health Team¹, Joyce Y. Tung¹*
- ¹23andMe, Inc., 899 W Evelyn Ave, Mountain View, CA, 94041 USA
- 8 *Correspondence should be addressed to J.Y.T. (joyce@23andme.com)

ABSTRACT

Current guidelines recommend *BRCA1* and *BRCA2* genetic testing for individuals with a personal or family history of certain cancers. Three *BRCA1/2* founder variants — 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) — are common in the Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish founder variants, evaluating two characteristics that are typically used to recommend individuals for *BRCA* testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information, 21% did not self-report any Jewish ancestry; of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided both ancestry and family history information, 44% did not have a first-degree family history of a *BRCA*-related cancer and, in the absence of a personal history of cancer, would therefore be unlikely to qualify for clinical genetic testing. These findings provide support for the growing call for broader access to *BRCA* genetic testing.

Keywords: BRCA1, BRCA2, genetic testing, Ashkenazi Jewish, family history

MAIN TEXT

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

BACKGROUND Pathogenic variants in the BRCA1 and BRCA2 genes are linked to an increased risk for female breast and ovarian cancer (including early-onset breast cancer), male breast cancer, prostate cancer, pancreatic cancer, and certain other cancers [1]. These variants are highly penetrant: Women with a variant have a 45-85% chance of developing breast cancer and up to a 46% chance of developing ovarian cancer by age 70 [2]. However, increased surveillance and prophylactic surgery (mastectomy and salpingo-oophorectomy) can greatly reduce the risk of breast and ovarian cancer in women carrying a BRCA1 or BRCA2 mutation [3]. The prevalence of pathogenic BRCA1 and BRCA2 variants is estimated to be between 1 in 300 and 1 in 800 in the general population [1,2]. Among individuals of Ashkenazi Jewish descent, three BRCA1/2 founder variants — 185delAG (c.68 69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) — are present at a frequency of ~1 in 40 [1]. Current U.S. guidelines limit BRCA1/2 genetic testing to individuals with a personal or family history of a relevant cancer, including early-onset breast cancer, multiple primary breast cancers, ovarian cancer, and certain other cancers [1,2,4]. In addition, Ashkenazi Jewish ancestry is sometimes used to recommend screening for individuals with a personal or family history of a single breast cancer at any age [1]. However, recent studies have found that about 50% of BRCA carriers have little or no family history of a relevant cancer [5-8]. These individuals would likely not qualify for clinical genetic testing unless they developed cancer themselves, representing a missed opportunity for cancer prevention. Because BRCA variants predispose to very high breast and ovarian cancer risks even among carriers without a family

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

history [5,9], these findings have spurred calls for broader access to BRCA genetic testing. among Ashkenazi Jews and in the general population [5-7,10,11]. The 23andMe database provides an ethnically diverse, generally unselected group of genotyped individuals. We sought to characterize a cohort of individuals who carry one or more of the three Ashkenazi Jewish founder variants as related to two characteristics that are typically used to recommend individuals for BRCA testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. We focused on these two characteristics because they can enable individuals to learn their BRCA status before developing cancer, thus providing opportunities for cancer prevention and/or early detection. **METHODS** Consented participants were drawn from the customer base of 23andMe. Data on Jewish ancestry and family cancer history were collected by self-report via online surveys. See Declarations for informed consent and protocol details; see Supplementary Information for survey questions. Analyses were run on phenotypic data collected before October 10, 2017. DNA extraction and genotyping were performed on saliva samples by CLIA-certified and CAPaccredited clinical laboratories of Laboratory Corporation of America. Samples were genotyped on one of four custom Illumina genotyping arrays: the HumanHap550+ Bead chip (two versions), the OmniExpress+ Bead chip, or a fully custom array; see [12] for additional details. Proportions of Ashkenazi Jewish genetic ancestry were estimated via an analysis of local genetic ancestry as described in [13]. To account for imprecision in genetic ancestry estimates, we characterized estimates of Ashkenazi Jewish genetic ancestry <1% as "not detectable."

RESULTS

We identified 2,853 individuals who carry one or more of the three Ashkenazi Jewish *BRCA1/2* founder variants (Table 1).

Table 1. Demographics of individuals carrying one or more of the three Ashkenazi Jewish *BRCA* founder variants

Age (years)	Men	Women
Overall	1539	1314
18-30	205 (13.3%)	186 (14.2%)
31-50	517 (33.6%)	461 (35.1%)
51-70	550 (35.7%)	510 (38.8%)
71+	267 (17.3%)	157 (11.9%)

We first characterized the ethnic backgrounds of the carriers. The three variants in this study are most common in people of Ashkenazi Jewish descent. However, among carriers who provided self-reported ancestry information, 21% did not report Jewish ancestry (Table 2).

Table 2. Self-reported Jewish ancestry in the cohort of *BRCA* carriers

Total BRCA carriers	2853
Provided self-reported ancestry	1967 (68.9%, of 2853)
- BRCA1 185delAG	748 (38.0%, of 1967)
- <i>BRCA1</i> 5382insC	415 (21.1%, of 1967)
- BRCA2 6174delT	811 (41.2%, of 1967)
- Self-reported Jewish ancestry	1552 (78.9%, of 1967)
- Did not self-report Jewish ancestry	415 (21.1%, of 1967)

The total number of *BRCA* variants detected exceeds the total number of individuals in the cohort because a small number of participants carry both a *BRCA1* and a *BRCA2* variant.


One possible explanation for the large fraction of carriers who did not report Jewish ancestry is that they were unaware of their Ashkenazi Jewish ancestry. To test this hypothesis, we explored the relationship between self-reported ancestry and genetic ancestry. As expected, individuals with a greater proportion of estimated Ashkenazi Jewish genetic ancestry were more likely to report Jewish ancestry (Table 3 and Figure 1); fewer than half of individuals with less than 20% Ashkenazi Jewish genetic ancestry (roughly equivalent to one grandparent or great-grandparent who was Ashkenazi Jewish) reported Jewish ancestry. Furthermore, most (62%, 258 of 415) of the *BRCA* carriers who reported no Jewish ancestry did have at least 1% Ashkenazi Jewish genetic ancestry. However, a lack of knowledge of Ashkenazi Jewish ancestry could not fully account for the 21% of carriers who did not report Jewish ancestry, as 8.4% (166 of 1,967) of individuals carrying an Ashkenazi Jewish founder variant had no detectable Ashkenazi Jewish genetic ancestry. This is consistent with the finding that at least two of these variants are also found in people of other ethnicities [14]. Nine individuals reported Jewish ancestry but had no detectable Ashkenazi Jewish genetic ancestry.

Table 3. Self-reported Jewish ancestry vs. estimated Ashkenazi Jewish genetic ancestry in 1,967 *BRCA* carriers

Likely last fully Ashkenazi Jewish ancestor	% calculated Ashkenazi Jewish genetic ancestry	Self-reported Jewish ancestry	Did not self-report Jewish ancestry
Self	85-100%	972	10
1 parent or 2-3 grandparents	40-84%	419	41
1 grandparent	20-39%	88	29
1 grandparent or great-grandparent	10-19%	33	34
1 great-grandparent	5-9%	7	17

More distant than great-grandparent	1-4%	24	127
No detectable Ashkenazi Jewish ancestry	0%	9	157

Figure 1. Self-reported Jewish ancestry vs. estimated Ashkenazi Jewish genetic ancestry in 1,967 *BRCA* carriers



% calculated Ashkenazi Jewish genetic ancestry

The primary criterion for *BRCA* genetic testing is a personal or family history of breast, ovarian, or certain other cancers (including prostate and pancreatic cancer). We therefore assessed whether the carriers in our cohort had any family history of cancer. 393 carriers provided family history information.

Among participants who reported Jewish ancestry, 41% reported no first-degree family history of a *BRCA*-related cancer (Table 4). Similarly, 54% of participants who did not report Jewish ancestry reported no first-degree family history of cancer. Although our family history data

differs substantially from guidelines used to determine genetic testing eligibility (which often include age of diagnosis and more than one cancer of certain types), this number is consistent with previous reports that about 50% of *BRCA* carriers would not be eligible for genetic testing based on family history alone [5-8].

Table 4. Self-reported family history of cancer in 393 BRCA carriers

		Total number who provided family history information	Reported a family history of breast or ovarian cancer	Reported a family history of prostate or pancreatic cancer	Reported no family history of breast, ovarian, prostate, or pancreatic cancer
First-degree family	Self-reported Jewish ancestry	310	139 (45%)	71 (23%)	127 (41%)
history	Did not self- report Jewish ancestry	83	33 (40%)	9 (11%)	45 (54%)
	Total	393	172 (44%)	80 (20%)	172 (44%)

Percentages in each row may not sum to 100%, because some participants reported a family history of more than one type of cancer.

DISCUSSION

In this study, we describe a largely unselected cohort of ~2,800 individuals who carry one or more of the three Ashkenazi Jewish *BRCA1/2* founder variants. In characterizing the ancestry and family cancer histories of these individuals, we made two key observations.

First, we found that a sizeable proportion (21%) of the carriers in our cohort do not self-report Jewish ancestry. Of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry, although frequently in very low percentages (Table 3 and Figure 1). Interestingly, 8% of all carriers have no detectable Ashkenazi Jewish genetic ancestry,

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

consistent with reports that BRCA1 185delAG and 5382insC are found in women of other ethnicities who are referred for clinical genetic testing [14]. Second, we observed that nearly half of individuals carrying an Ashkenazi Jewish BRCA variant have no first-degree family history of a BRCA-related cancer and, in the absence of a personal cancer history, would therefore be unlikely to qualify for clinical genetic testing. This percentage is consistent with published reports that about 50% of BRCA carriers lack a strong family history of cancer [5-8]. Limitations of this study include a potential ascertainment bias related to family cancer history, as individuals with such histories may be more likely to answer questions about family cancer history. In addition, due to the limited depth of our family history survey, we defined family history as having a first-degree relative with breast, ovarian, prostate, or pancreatic cancer; clinical testing criteria are typically stricter, requiring an early age of diagnosis and/or more than one affected family member. Together, these two points suggest that our estimate of the fraction of individuals who would be ineligible for testing based on family history alone under existing screening guidelines is likely lower than the true fraction. Finally, because not all individuals in this study provided ancestry and family history information, the number of individuals included in some analyses is fairly small. Our data suggest that a sizeable fraction of individuals with detectable Ashkenazi Jewish genetic ancestry are unaware of that ancestry. This phenomenon is likely not unique to Ashkenazi Jewish ancestry. In addition to BRCA-related cancers, many other conditions are more common in specific ancestral groups, including Tay-Sachs disease, Canavan disease, and Gaucher disease type 1 in Ashkenazi Jews; sickle cell anemia in individuals with African ancestry; and beta-thalassemia in individuals with Mediterranean and certain other ancestries.

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

For individuals who are unaware of their genetic ancestry, perceived risk for diseases could thus differ substantially from actual risk, which could lead to missed opportunities for genetic screening, prevention, and early intervention. In recent years, several groups have called for broader access to BRCA genetic testing among Ashkenazi Jews and among women in the general population [5-7,10,11]. Among Ashkenazi Jews, where testing for the three founder variants can identify most BRCA carriers, populationwide screening is cost-effective or even cost-saving [15]; in other ethnicities, more comprehensive genetic testing would be required to identify most individuals carrying a BRCA variant, but depending on the source of testing, this may also be cost-effective [16]. Our data provide support for this growing call for expanded BRCA testing. Such testing would enable women and men with a BRCA variant to learn their status, take steps to reduce their cancer risk, and encourage cascade testing of close family members. **DECLARATIONS** Ethics approval and consent to participate All participants provided informed consent and answered surveys online according to a research protocol approved by Ethical and Independent Review Services, an external AAHRPPaccredited institutional review board. Availability of data All data generated or analyzed during this study are included in the manuscript. **Competing interests** R.I.T., S.B.L., B.L.K. M.H.M., J.Y.T., and members of The 23andMe Health Team are current or former employees of and have stock, stock options, or both, in 23andMe, Inc.

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

Funding No external funding was received for this study. **Authors' contributions** Study concept and design: J.Y.T. and R.I.T. Acquisition and analysis of data: J.Y.T., S.B.L., B.L.K, and M.H.M. Interpretation of data: R.I.T., S.B.L., B.L.K, M.H.M., and J.Y.T. Drafting of the manuscript: R.I.T. Critical revision of the manuscript for important intellectual content: R.I.T., S.B.L., B.L.K, M.H.M., and J.Y.T. Support and infrastructure to enable the research presented here: The 23andMe Health Team. **Acknowledgements** We thank the research participants and employees of 23andMe for making this work possible. We also thank Uta Francke, Jennifer C. McCreight, and Elizabeth S. Noblin for critical review of the manuscript; David A. Hinds for scientific input; and Catherine Wilson for supporting the ancestry and cancer family history surveys. The 23andMe Health Team: Robert K. Bell, Katarzyna Bryc, Alison L. Chubb, Stacey B. Detweiler, Anne E. Greb, Esther Kim, Michaela Johnson, Joanna L. Mountain, Jamaica R. Perry, Jeffrey D. Pollard, Shirley Wu. REFERENCES 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 3.2019. Available at:

- 218 https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed 28
- 219 Mar 2019.
- 220 2. Committee on Practice Bulletins-Gynecology, Committee on Genetics, Society of
- 221 Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer
- 222 Syndrome. Obstet Gynecol. 2017;130(3):e110-e126.
- 223 3. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated
- with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl
- 225 Cancer Inst. 2009;101(2):80-7.
- 4. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and
- genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force
- recommendation statement. Ann Intern Med. 2014;160(4):271-81.
- 5. Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M,
- Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-
- 231 Lahad E. Population-based screening for breast and ovarian cancer risk due to BRCA1 and
- 232 BRCA2. Proc Natl Acad Sci U S A. 2014;111(39):14205-10.
- 233 6. Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L,
- Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C,
- Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I. Population testing for cancer
- predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized
- controlled trial. J Natl Cancer Inst. 2015;107(1):379.
- 238 7. Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA. A comparison of
- 239 the detection of BRCA mutation carriers through the provision of Jewish population-based
- genetic testing compared with clinic-based genetic testing. Br J Cancer. 2013;109(3):777-9.
- 241 8. Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, Rocha
- 242 H, Savatt JM, Evans AE, Butry LM, Lazzeri AL, Lindbuchler DM, Flansburg CN, Leeming R,
- Vogel VG, Lebo MS, Mason-Suares HM, Hoskinson DC, Abul-Husn NS, Dewey FE, Overton

- JD4 Reid JG, Baras A, Willard HF, McCormick CZ, Krishnamurthy SB, Hartzel DN, Kost KA,
- Lavage DR, Sturm AC, Frisbie LR, Person TN, Metpally RP, Giovanni MA, Lowry LE,
- Leader JB, Ritchie MD, Carey DJ, Justice AE, Kirchner HL, Faucett WA, Williams MS,
- 247 Ledbetter DH, Murray MF. Exome Sequencing-Based Screening for BRCA1/2 Expected
- 248 Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open.
- 249 2018;1(5):e182140.
- 9. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S,
- van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF,
- 252 Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale
- D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis
- S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van
- der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB,
- Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J,
- 257 Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E,
- 258 Gerdes AM, Arver B, Olsson H. Risks of Breast, Ovarian, and Contralateral Breast Cancer
- 259 for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.
- 10. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2:
- 261 2014 Lasker Award. JAMA. 2014;312(11):1091-2.
- 262 11. Akbari MR, Gojska N, Narod SA. Coming of age in Canada: a study of population-based
- genetic testing for breast and ovarian cancer. Curr Oncol. 2017;24(5):282-283.
- 12. Sanchez-Roige S, Fontanillas P, Elson SL, 23andMe Research Team, Pandit A, Schmidt
- 265 EM, Foerster JR, Abecasis GR, Gray JC, de Wit H, Davis LK, MacKillop J, Palmer AA.
- Genome-wide association study of delay discounting in 23,217 adult research participants of
- 267 European ancestry. Nat Neurosci. 2018;21(1):16-18.
- 268 13. Durand, E.Y., Do, C.B., Mountain, J.L., Macpherson, J.M. Ancestry Composition: A Novel,
- 269 Efficient Pipeline for Ancestry Deconvolution | bioRxiv. Available at:

https://www.biorxiv.org/content/10.1101/010512v1. Accessed 28 Mar 2019.
14. Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, Ward BE, Scholl TA, Noll WW. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115(10):2222-33.
15. Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I. Costeffectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J Natl Cancer Inst. 2015;107(1):380.
16. Long EF, Ganz PA. Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making. JAMA Oncol. 2015;1(9):1217-8.

SUPPLEMENTARY INFORMATION

2	
3	Jewish ancestry
4	Do you have any Jewish ancestry?
5	()Yes
6	()No
7	()I'm not sure
8	
9	Participants who answered "Yes" were counted as self-reporting Jewish ancestry; participants
10	who answered "No" were counted as not self-reporting Jewish ancestry; and participants who
11	answered "I'm not sure" were not counted.
12	
13	Family history
14	Participants provided information about family history of cancer in one of three surveys, which
15	included slightly different versions of the family history questions. Functionally, there were two
16	versions of the family history questions (described below). Version 1 was in one survey while
17	Version 2 was in two surveys. Relevant questions from each survey are excerpted below.
18	
19	Version 1
20	Is your family's history of cancer completely unknown to you for some reason, such as being
21	adopted?
22	() Yes
23	() No
24	
25	Please indicate below whether your biological parents or grandparents have ever had cancer.
26	[Grandparental history was not used.]
27	Your mother
28	()Yes
29	()No
30	()I'm not sure
31	
32	Your father
33	()Yes
34	()No
35	()I'm not sure
36	
37	Have any of your other biological relatives, listed below, had cancer?
38	Your child(ren)
39	()Yes
40	()No
41	()Not applicable
42	()I'm not sure
43	
44	Your sister(s)

45	()Yes
46	()No
47	()Not applicable
48	()I'm not sure
49	
50	Your brother(s)
51	()Yes
52	()No
53	()Not applicable
54	()I'm not sure
55	
56	{Where <female relative=""> could be "mother" or "sister"}</female>
57	What type(s) of cancer was your <female relative=""> diagnosed with? Please check all that apply.</female>
58	[] Adrenal gland cancer
59	[] Anal cancer
60	[] Bladder cancer
61	[] Biliary tract cancer
62	[] Brain cancer
63	[] Breast cancer
64	[] Cervical cancer
65	[] Colon/colorectal cancer
66	[] Endometrial or uterine cancer
67	[] Esophageal cancer
68	[] Gallbladder cancer
69	[] Hodgkin's lymphoma
70	[] Kidney/renal cancer
71	[] Leukemia, any type
72	[] Liver/bile ducts (hepatobiliary) cancer
73	[] Lung cancer
74	[] Melanoma
75	[] Mouth (oral) cancer
76	[] Non-Hodgkin's lymphoma
77	[] Pancreatic cancer
78	[] Ovarian cancer
79	[] Salivary gland cancer
80	[] Sarcoma, any type
81	[] Skin cancer (not melanoma)
82	[] Small intestine/duodenal cancer
83	[] Stomach/gastric cancer
84	[] Throat cancer
85	[] Thyroid cancer
86	[] Ureter/renal pelvis cancer
87	[] Vaginal cancer
88	[1 Vulval cancer

89	[] Another type of cancer:
90	[] I'm not sure
91	
92	{Where <male relative=""> could be "father" or "brother"}</male>
93	What type(s) of cancer was your <male relative=""> diagnosed with? Please check all that apply</male>
94	[] Adrenal gland cancer
95	[] Anal cancer
96	[] Bladder cancer
97	[] Biliary tract cancer
98	[] Brain cancer
99	[] Breast cancer
100	[] Colon/colorectal cancer
101	[] Esophageal cancer
102	[] Gallbladder cancer
103	[] Hodgkin's lymphoma
104	[] Kidney/renal cancer
105	[] Leukemia, any type
106	[] Liver/bile ducts (hepatobiliary) cancer
107	[] Lung cancer
108	[] Melanoma
109	[] Mouth (oral) cancer
110	[] Non-Hodgkin's lymphoma
111	[] Pancreatic cancer
112	[] Prostate cancer
113	[] Salivary gland cancer
114	[] Sarcoma, any type
115	[] Skin cancer (not melanoma)
116	[] Small intestine/duodenal cancer
117	[] Stomach/gastric cancer
118	[] Testicular cancer
119	[] Throat cancer
120	[] Thyroid cancer
121	[] Ureter/renal pelvis cancer
122	[] Another type of cancer:
123	[] I'm not sure
124	
125	What type(s) of cancer was your child(ren) diagnosed with? Please check all that apply.
126	[] Adrenal gland cancer
127	[] Anal cancer
128	[] Bladder cancer
129	[] Biliary tract cancer
130	[] Brain cancer
131	[] Breast cancer
132	[] Cervical cancer

133	[] Colon/colorectal cancer
134	[] Endometrial or uterine cancer
135	[] Esophageal cancer
136	[] Gallbladder cancer
137	[] Hodgkin's lymphoma
138	[] Kidney/renal cancer
139	[] Leukemia, any type
140	[] Liver/bile ducts (hepatobiliary) cancer
141	[] Lung cancer
142	[] Melanoma
143	[] Mouth (oral) cancer
144	[] Non-Hodgkin's lymphoma
145	[] Pancreatic cancer
146	[] Prostate cancer
147	[] Ovarian cancer
148	[] Salivary gland cancer
149	[] Sarcoma, any type
150	[] Skin cancer (not melanoma)
151	[] Small intestine/duodenal cancer
152	[] Stomach/gastric cancer
153	[] Testicular cancer
154	[] Throat cancer
155	[] Thyroid cancer
156	[] Ureter/renal pelvis cancer
157	[] Vaginal cancer
158	[] Vulval cancer
159	[] Another type of cancer:
160	[] I'm not sure
161	
162	Have you ever been diagnosed with any of these hereditary cancer syndromes?
163	[] Cowden syndrome
164	[] Familial adenomatous polyposis
165	[] Hereditary breast and ovarian cancer syndrome (HBOC)
166	[] Li-Fraumeni syndrome
167	[] Lynch syndrome (hereditary non-polyposis colorectal cancer syndrome)
168	[] Multiple endocrine neoplasias
169	[] Von Hippel-Lindau Disease
170	[] I'm not sure
171	[] None of the above
172	
173	Version 2
174	Please indicate below whether your biological parents, siblings, or children have ever had
175	cancer.
176	Your mother

177	()Yes
178	()No
179	()I'm not sure
180	
181	Your father
182	()Yes
183	()No
184	()I'm not sure
185	
186	Your sibling(s)
187	()Yes
188	()No
189	()I'm not sure
190	
191	Your child(ren)
192	()Yes
193	()No
194	()I'm not sure
195	
196	How many biological siblings do you have?
197	
198	How many biological children do you have?
199	
200	What type(s) of cancer was your biological mother diagnosed with or treated for? Please select
201	all that apply.
202	[] Bladder cancer
203	[] Brain cancer
204	[] Breast cancer
205	[] Colon/colorectal cancer
206	[] Endometrial or uterine cancer
207	[] Hodgkin's lymphoma
208	[] Kidney/renal cancer
209	[] Leukemia, any type
210	[] Liver cancer
211	[] Lung cancer
212	[] Myeloma
213	[] Non-Hodgkin's lymphoma
214	[] Ovarian cancer
215	[] Pancreatic cancer
216	[] Skin cancer
217	[] Stomach cancer
218	[] Thyroid cancer
219	[] Another type of cancer
220	[] I'm not sure

221	
222	What type(s) of cancer was your biological father diagnosed with or treated for? Please select
223	all that apply.
224	[] Bladder cancer
225	[] Brain cancer
226	[] Colon/colorectal cancer
227	[] Esophageal cancer
228	[] Hodgkin's lymphoma
229	[] Kidney/renal cancer
230	[] Leukemia, any type
231	[] Liver cancer
232	[] Lung cancer
233	[] Mouth (oral) cancer
234	[] Myeloma
235	[] Non-Hodgkin's lymphoma
236	[] Pancreatic cancer
237	[] Prostate cancer
238	[] Skin cancer
239	[] Stomach cancer
240	[] Thyroid cancer
241	[] Another type of cancer
242	[] I'm not sure
243	
244	How many of your biological siblings have ever had cancer?
245	
246	What type(s) of cancer was your biological sibling(s) diagnosed with or treated for? Please
247	select all that apply.
248	[] Bladder cancer
249	[] Brain cancer
250	[] Breast cancer
251	[] Colon/colorectal cancer
252	[] Endometrial or uterine cancer
253	[] Esophageal cancer
254	[] Hodgkin's lymphoma
255	[] Kidney/renal cancer
256	[] Leukemia, any type
257	[] Liver cancer
258	[] Lung cancer
259	[] Mouth (oral) cancer
260	[] Myeloma
261	[] Non-Hodgkin's lymphoma
262	[] Ovarian cancer
263	[] Pancreatic cancer
264	[] Prostate cancer

265	[] Stomach cancer
266	[] Skin cancer
267	[] Thyroid cancer
268	[] Another type of cancer
269	[] I'm not sure
270	
271	How many of your biological children have ever had cancer?
272	
273	What type(s) of cancer was your biological child(ren) diagnosed with or treated for? Please
274	select all that apply.
275	[] Bladder cancer
276	[] Brain cancer
277	[] Breast cancer
278	[] Colon/colorectal cancer
279	[] Endometrial or uterine cancer
280	[] Esophageal cancer
281	[] Hodgkin's lymphoma
282	[] Kidney/renal cancer
283	[] Leukemia, any type
284	[] Liver cancer
285	[] Lung cancer
286	[] Mouth (oral) cancer
287	[] Myeloma
288	[] Non-Hodgkin's lymphoma
289	[] Ovarian cancer
290	[] Pancreatic cancer
291	[] Prostate cancer
292	[] Stomach cancer
293	[] Skin cancer
294	[] Thyroid cancer
295	[] Another type of cancer
296	[] I'm not sure
297	
298	Have any of your biological parents, siblings, or children ever been diagnosed with any of these
299	hereditary cancer syndromes?
300	[] Cowden syndrome
301	[] Familial adenomatous polyposis
302	[] Hereditary breast and ovarian cancer syndrome (HBOC)
303	[] Li-Fraumeni syndrome
304	[] Lynch syndrome (hereditary non-polyposis colorectal cancer syndrome)
305	[] Multiple endocrine neoplasias
306	[] Von Hippel-Lindau Disease
307	[] I'm not sure
308	[] None of the above